CCM
TVTX icon

Consonance Capital Management’s Travere Therapeutics TVTX Stock Holding History

Consonance Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,314,421
Closed -$33.8M – 36
2020
Q1 		$33.8M Hold
2,314,421
– – 2.51% 18
2019
Q4 		$32.9M Hold
2,314,421
– – 2.01% 20
2019
Q3 		$26.8M Sell
2,314,421
-1,498,095
-39% -$24.8M 2.65% 17
2019
Q2 		$76.6M Sell
3,812,516
-219,607
-5% -$4.34M 5.42% 5
2019
Q1 		$91.2M Hold
4,032,123
– – 5.76% 6
2018
Q4 		$91.2M Buy
4,032,123
+117,941
+3% +$2.93M 6.71% 6
2018
Q3 		$112M Buy
3,914,182
+70,811
+2% +$2.02M 6.05% 2
2018
Q2 		$105M Buy
3,843,371
+150,000
+4% +$3.99M 6.76% 4
2018
Q1 		$82.6M Buy
3,693,371
+48,933
+1% +$1.17M 7.55% 4
2017
Q4 		$76.8M Buy
3,644,438
+138,834
+4% +$3.17M 6.94% 6
2017
Q3 		$87.3M Buy
3,505,604
+1,067,064
+44% +$23.5M 9.65% 2
2017
Q2 		$47.3M Buy
2,438,540
+306,400
+14% +$5.56M 5.57% 11
2017
Q1 		$39.4M Sell
2,132,140
-640,016
-23% -$12.5M 4.13% 13
2016
Q4 		$52.5M Sell
2,772,156
-312,791
-10% -$6.4M 5.76% 6
2016
Q3 		$69M Buy
3,084,947
+385,000
+14% +$7.33M 6.65% 6
2016
Q2 		$48.1M Sell
2,699,947
-30,000
-1% -$486K 6.81% 6
2016
Q1 		$37.3M Sell
2,729,947
-730,376
-21% -$11.1M 5.64% 10
2015
Q4 		$66.8M Buy
3,460,323
+10,000
+0.3% +$200K 8.95% 6
2015
Q3 		$69.9M Buy
3,450,323
+50,000
+1% +$1.48M 9.84% 4
2015
Q2 		$113M Buy
3,400,323
+292,613
+9% +$8.01M 11.33% 1
2015
Q1 		$74.5M Buy
3,107,710
+556,175
+22% +$8.48M 6.78% 6
2014
Q4 		$31.2M Buy
2,551,535
+1,012,076
+66% +$10.5M 4.02% 11
2014
Q3 		$13.9M Buy
+1,539,459
New +$18.1M 1.91% 18

Other funds holding TVTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Consonance Capital Management's TVTX Position: Q2 2020 in Review

Consonance Capital Management sold out of Travere Therapeutics (TVTX) in Q2 2020, closing a stake of 2,314,421 shares — an estimated $33.8M sold.

Consonance Capital Management first reported a position in TVTX in Q3 2014 and held it in 23 quarters. The position peaked at $113M in Q2 2015. 147 funds tracked by Wall St. Rank hold TVTX as of Q2 2020.

  • Consonance Capital Management reported no remaining Travere Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Consonance Capital Management sold 2,314,421 Travere Therapeutics shares in Q2 2020, an estimated $33.8M.
  • Consonance Capital Management first reported a position in Travere Therapeutics in Q3 2014 and held it in 23 quarters.
  • Consonance Capital Management's Travere Therapeutics position peaked at $113M in Q2 2015.
  • 147 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2020.

Based on Consonance Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.